請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56712
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟(Li-Jiuan Shen) | |
dc.contributor.author | Hsing-Yu Lin | en |
dc.contributor.author | 林星羽 | zh_TW |
dc.date.accessioned | 2021-06-16T05:43:43Z | - |
dc.date.available | 2019-10-15 | |
dc.date.copyright | 2014-10-15 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-11 | |
dc.identifier.citation | 1. Kollef MH, Zilberberg MD, Shorr AF, et al. Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort study. J Infect 2011;62:130-5.
2. Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011;53:144-9. 3. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000;57 Suppl 2:S4-9. 4. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-42. 5. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10; quiz 1-2. 6. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17:479-501. 7. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98. 8. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007;44:1536-42. 9. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis 2011;52:969-74. 10. Brown DL, Lalla CD, Masselink AJ. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug. Ther Drug Monit 2013;35:443-9. 11. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14. 12. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-15. 13. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44. 14. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6. 15. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010;123:182 e1-7. 16. Que Y-A, Moreillon P. Staphylococcus aureus (Including Staphylococcal Toxic Shock). In: Mandell GL, Bennett J, Dolin R, eds. Mandell: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Elsevier Inc.; 2010:2543-78. 17. WHO. Antimicrobial resistance: global report on surveillance.2014. 18. Lai CC, Wang CY, Chu CC, et al. Correlation between antimicrobial consumption and resistance among Staphylococcus aureus and enterococci causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. Eur J Clin Microbiol Infect Dis 2011;30:265-71. 19. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2012. 20. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev 2012;25:362-86. 21. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46 Suppl 5:S344-9. 22. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-71. 23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. 24. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2013;19:1163-8. 25. Tenover FC, Moellering RC, Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44:1208-15. 26. Bloomgren BJ, Laible BR. Etest versus vitek 2 vancomycin minimum inhibitory concentration testing methods for methicillin-resistant staphylococcus aureus: an antimicrobial stewardship initiative to evaluate the degree of discordance among methods at a rural tertiary hospital. J Pharm Pract 2013;26:415-9. 27. Chen SY, Liao CH, Wang JL, et al. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2014;69:211-8. 28. Welsh KJ, Skrobarcek KA, Abbott AN, et al. Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin. J Clin Microbiol 2011;49:3669-72. 29. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011;52:975-81. 30. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-20. 31. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011;204:340-7. 32. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55. 33. Budavari S. The Merck index: an encyclopedia of chemicals, drugs, and biological s1989. 34. Katzung BG. Basic & Clinical Pharmacology. 10 th ed: McGraw-Hill. 35. Barbara E. Murray ECN. Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), and Lipopeptides (Daptomycin). Mandell: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, . 7th ed. PA: Churchill Livingstone, An Imprint of Elsevier; 2009 36. AHFS Drug InformationR. 56th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2014. 37. Chang FY, Peacock JE, Jr., Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82:333-9. 38. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008;52:192-7. 39. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996;38:589-97. 40. Duffull SB, Begg EJ, Chambers ST, Barclay ML. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrob Agents Chemother 1994;38:2480-2. 41. Lowdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998;42:2739-44. 42. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665-72. 43. Moise-Broder PA. Vancomycin. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied pharmacokinetics & pharmacodynamics: principles of therapeutic drug monitoring MD: Lippincott Williams & Wilkins; 2005:328-40. 44. Geraci JE. Vancomycin. Mayo Clin Proc 1977;52:631-4. 45. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-8. 46. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006;57:699-704. 47. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416. 48. Knudsen JD, Fuursted K, Espersen F, Frimodt-Moller N. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob Agents Chemother 1997;41:1910-5. 49. Peetermans WE, Hoogeterp JJ, Hazekamp-van Dokkum AM, van den Broek P, Mattie H. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990;34:1869-74. 50. DeRyke, C. Andrew DeRyke P, Alexander D. Optimizing Vancomycin Dosing Through Pharmacodynamic Assessment Targeting Area Under the Concentration-Time Curve/Minimum Inhibitory Concentration. Hosp Pharm 2009;44:751-65. 51. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130:947-55. 52. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2013;57:1654-63. 53. Ebert SL CW. In vivo cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and resistant S. aureus. . Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemother (New York): Washington: American Society for Microbiology; 1987:173. 54. Dudley M GD, Corcoran E, Liu C, Sorensen K, Tembe V. Pharmacokinetic-pharmacodynamic (PK-PD) indices for vancomycin treatment of susceptible (VSSA) and intermediate (VISA) S. aureus in the neutropenic murine thigh model. Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemother (San Francisco): Washington: American Society for Microbiology; 1999:49. 55. Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother 2012;56:634-8. 56. Jung Y, Song KH, Cho JE, et al. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 2013;43:179-83. 57. Gawronski KM, Goff DA, Brown J, Khadem TM, Bauer KA. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther 2013;35:772-9. 58. Neely MN, Youn G, Jones B, et al. Are vancomycin troughs adequate for optimal dosing? Antimicrob Agents Chemother 2013;58:309-16. 59. Matzke GR, Halstenson CE, Olson PL, Collins AJ, Abraham PA. Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987;9:422-5. 60. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257-82. 61. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994;16:513-8. 62. Aldaz A, Ortega A, Idoate A, Giraldez J, Brugarolas A. Effects of hepatic function on vancomycin pharmacokinetics in patients with cancer. Ther Drug Monit 2000;22:250-7. 63. Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother 1993;37:1132-6. 64. Morita K, Yamaji A. Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels. Ther Drug Monit 1995;17:107-12. 65. Chen Y, Norris RL, Schneider JJ, Ravenscroft PJ. The influence of vancomycin concentration and the pH of plasma on vancomycin protein binding. J Pharmacol Toxicol Methods 1992;28:57-60. 66. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42 Suppl 1:S35-9. 67. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988;32:848-52. 68. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25:433-7. 69. Vandecasteele SJ, De Vriese AS. Vancomycin Dosing in Patients on Intermittent Hemodialysis. Seminars in Dialysis 2011;24:50-5. 70. Moellering RC, Jr., Krogstad DJ, Greenblatt DJ. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis 1981;3 suppl:S230-5. 71. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830-8. 72. Tanaka A, Aiba T, Otsuka T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother 2010;54:778-82. 73. Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984;36:803-10. 74. Guay DR, Vance-Bryan K, Gilliland S, Rodvold K, Rotschafer J. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993;33:918-22. 75. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother 2012;67:1305-10. 76. Leong JV, Boro MS, Winter M. Determining vancomycin clearance in an overweight and obese population. Am J Health Syst Pharm 2011;68:599-603. 77. Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy 2012;32:604-12. 78. Park EJ, Pai MP, Dong T, et al. The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. Ann Pharmacother 2012;46:317-28. 79. Nelson WK, Formica RN, Jr., Cooper DL, Schwartz PE, Rutherford TJ. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. J Oncol Pharm Pract 2012;18:323-32. 80. Wilhelm SM, Kale-Pradhan PB. Estimating creatinine clearance: a meta-analysis. Pharmacotherapy 2011;31:658-64. 81. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009;66:642-8. 82. Blanchet B, Jullien V, Vinsonneau C, Tod M. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008;47:635-54. 83. Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomycin in haemodialysis patients. Crit Care 2002;6:313-6. 84. Vandecasteele SJ, De Bacquer D, De Vriese AS. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 microg/mL in persons undergoing hemodialysis. Clin Infect Dis 2011;53:124-9. 85. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-51; quiz 59. 86. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49:1-16. 87. Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 2006;31:447-54. 88. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012;68:1243-55. 89. Burgess LD, Drew RH. Comparison of the Incidence of Vancomycin-Induced Nephrotoxicity in Hospitalized Patients with and without Concomitant Piperacillin-Tazobactam. Pharmacotherapy 2014. 90. Han H, An H, Shin KH, et al. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring. Ther Drug Monit 2014. 91. Moh'd H, Kheir F, Kong L, et al. Incidence and predictors of vancomycin-associated nephrotoxicity. South Med J 2014;107:383-8. 92. Pollard TA, Lampasona V, Akkerman S, et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int 1994;45:232-7. 93. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009;29:562-77. 94. 王耀輝. 臺大醫院病人群vancomycin靜脈輸注起始給藥模式之研究 [學位論文]. 臺北: 國立台灣大學; 1997. 95. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41. 96. Dowling TC. Clinical assessment of kidney function. In: DiPiro JT, Talber Rl, Yee GC, Matzke GR, Wells BG, LM P, eds. Pharmacotherapy: A Pathophysiologic Approach 8th ed. New York: McGraw-Hill Companies; 2011:719-39. 97. 陳淑君. 臺大醫院住院病人使用萬古黴素(vancomycin)起始給藥方法之評估及藥物動力學參數之分析 [學位論文]. 臺北: 國立臺灣大學; 2003. 98. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36:1418-23. 99. Pan SC, Wang JT, Lauderdale TL, et al. Epidemiology and staphylococcal cassette chromosome mec typing of methicillin-resistant Staphylococcus aureus isolates in Taiwan: A multicenter study. J Formos Med Assoc 2014;113:409-16. 100. Ghosh N, Chavada R, Maley M, van Hal S. Impact of Source of Infection and Vancomycin AUC /MIC targets on Treatment failure in patients with Methicillin Resistant Staphylococcus Aureus Bacteraemia. Clin Microbiol Infect 2014. 101. Jin SJ, Yoon JH, Ahn BS, Chung JA, Song YG. Underestimation of the calculated area under the concentration-time curve based on serum creatinine for vancomycin dosing. Infection & chemotherapy 2014;46:21-9. 102. Zelenitsky S, Rubinstein E, Ariano R, et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents 2013;41:255-60. 103. Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM. Is vancomycin MIC 'creep' method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol 2012;50:318-25. 104. Ludwig F, Edwards B, Lawes T, Gould IM. Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2012;50:3383-7. 105. Louria DB, Kaminski T, Buchman J. VAncomycin in severe staphylococcal infections. Arch Intern Med 1961;107:225-40. 106. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982;97:344-50. 107. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992;36:1766-9. 108. Ahmed A, Jafri H, Lutsar I, et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1999;43:876-81. 109. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N. Pharmacodynamics of Glycopeptides in the Mouse Peritonitis Model of Streptococcus pneumoniae or Staphylococcus aureus Infection. Antimicrob Agents Chemother 2000;44:1247-54. 110. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 2003;26:876-9. 111. Moellering RC, Jr., Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94:343-6. 112. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976;4:183-95. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56712 | - |
dc.description.abstract | 研究背景
萬古黴素(vancomycin)為治療抗藥性金黃色葡萄球菌(MRSA)感染症之首選抗生素,臨床上可以進行療劑監測(therapeutic drug monitoring, TDM)達到適當療效。目前治療指引建議臨床上採用谷藥品濃度(trough concentration, Ctrough)做為監測指標,但有文獻指出vancomycin血中濃度對時間之曲線下面積(AUC)/最低抑菌濃度(MIC)比值才是能準確預測vancomycin治療結果的參數。隨著近年研究指出Ctrough和AUC/MIC的相關性不如預期,確認哪一種參數最能預測vancomycin臨床療效並且應用於臨床實務中是重要的議題。 研究目的 (1)驗證AUC/MIC是否更適於Ctrough預測vancomycin臨床治療效果、(2)評估華人是否適用國外文獻中的群體藥動學公式來預測vancomycin療效,(3)探討vancomycin Ctrough和AUC/MIC相關性。 研究設計與方法 本研究回溯性觀察西元2001年至2011年臺大醫院急診就醫確診MRSA菌血症、並且在血液培養後3日內開始vancomycin靜脈注射治療、治療大於3日以上達血中濃度穩定而進行療劑監測之非透析病人。以邏輯斯迴歸分析vancomycin Ctrough和以群體藥動學公式計算之AUC/MIC兩者分別與30日存活結果之關聯性,並以分類迴歸分析方法(CART)、ROC曲線評估各公式計算之AUC/MIC對30日存活結果預測力。 研究結果 一共432位急診就醫確診MRSA菌血症病人,排除196位vancomycin用藥資料不足、83位進行血液透析病人、30位vancomycin用藥時間不符研究條件,最終共123人進入分析。平均年齡63 ± 17歲,男性比例57%,30日死亡人數為19人(15.4%)。分析結果顯示Ctrough於30日存、亡兩組間無統計顯著差異(12.2 ± 5.7 v.s. 14.4 ± 7.5 mg/L, p=0.32),而群體藥動學公式計算之AUCRodvold /MICEtest是最具30日存亡預測力、在30日存活組中統計顯著較高(334.6 ± 124.6 vs. 258.1 ± 124.1; p=0.01)。AUCRodvold /MICEtest≧220經多變項迴歸分析後,與30日死亡顯著負相關(aOR=0.27, 95% CI 0.09-0.83, p=0.02)。此外也觀察到Ctrough和AUCRodvold、AUCRodvold /MICEtest之間並無良好的線性關係(依序為r=0.451, p<0.01; r=0.27, p<0.01)。 結論 以群體藥動學公式計算之AUC/MIC比Ctrough更適合預測vancomycin臨床療效,其中以AUCRodvold /MICEtest≧220最具預測力。建議臨床進行vancomycin療劑監測時,應使用AUC/MIC做為監測指標,而非Ctrough。未來可進行前瞻性隨機之臨床試驗進一步確認本研究的結果。 | zh_TW |
dc.description.abstract | Background
Vancoymycin is an important antibiotic for the treatment of methicillin resistant Staphylococcus aureus (MRSA). Trough concentration (Ctrough) of vancomycin has been used as a pharmacokinetic/pharmacodynamic (PK/PD) parameter in therapeutic drug monitoring to ensure the outcome of the treatment for years. However, some studies showed that the ratio of area under the curve of vancomycin and minimum inhibitory concentration of the bacteria (AUC/MIC) was a better indicator for PK/PD of vancomycin in clinical practice. In addition, poor relation between Ctrough and AUC/MIC of vancomycin has been demonstrated. It is an important issue to clarify which is the most appropriate parameter correlated with clinical effectiveness of vancomycin in patients with infection of MRSA. Objectives This study was to (1) determine which parameter, AUC/MIC or Ctrough, have a better association with the outcome of vancomycin, (2) validate that calculated AUC/MIC by using population equation can be used to predict vancomycin clinical effectiveness in Chinese population, and (3) evaluate the correlation between vancomycin Ctrough and calculated AUC/MIC. Materials and Methods This retrospective cohort study was conducted in the Emergency Department of National Taiwan University Hospital. Non-dialysis patients diagnosed with MRSA bacteremia receiving vancomycin therapy in 3 days after positive blood culture and undergoing therapeutic drug monitoring between 2001 and 2011 were included. AUC/MICs of vancomycin were calculated with published equations and Ctrough were retrieved from medical charts. Subsequetnly, the association of 30-day all-cause mortality and PK/PD parameters was analyzed with receiver operating characteristic curve (ROC) and logistic regression. Cut-off point of AUC/MICs associated with reduced 30-day all-cause mortality was derived using classification and regression tree analysis (CART). Results Total 432 patients diagnosed with MRSA bacteremia were included. Three hundred and nine of these patients were excluded (196 patients, insufficient data about vancomycin dosing and serum concentration; 83 patients, undergoing dialysis; 30 patients, delayed vancomycin therapy or shorter than 3 days), leaving 123 patients for final analysis. Ninteen of 123 (15.4%) patients expired in 30 days. No significant difference was observed in Ctrough between two groups (12.2 ± 5.7 v.s. 14.4 ± 7.5 mg/L, p=0.32). However, calculated AUC/MICs using vancomycin clearance derived from Rodvold equation and MIC value of E-test (AUCRodvold /MICEtest), the best method to predict 30-day outcome in our study, was significantly different between 30-day survivors and non-survivors (334.6 ± 124.6 vs. 258.1 ± 124.1; p=0.01). AUCRodvold /MICEtest above 220 was associated with reduced mortality and remained significant in a multivariable model (aOR=0.27, 95% CI 0.09-0.83, p=0.02). Poor linear relations between Ctrough and both of AUCRodvold and AUCRodvold /MICEtest were also observed (r=0.451, p<0.01; r=0.27, p<0.01, respectively). Conclusions Calculated AUC/MIC is a better parameter which associates with clinical effectiveness of vancomycin compared to the Ctrough. AUCRodvold /MICEtest≧220 can be used as a target to improve clinical effectiveness of vancomycin in clinical practice. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T05:43:43Z (GMT). No. of bitstreams: 1 ntu-103-R01451009-1.pdf: 7113855 bytes, checksum: f565c822b7f9da072b0bc8281e71ebf3 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 口試委員審定書 i
謝辭 ii 中文摘要 iii Abstract v 目錄 viii 表目錄 xi 圖目錄 xii 附錄目錄 xiii 第1章 前言 1 第2章 文獻回顧 3 第2-1節 抗藥性金黃色葡萄球菌 3 2.1.1. 盛行率及死亡率 3 2.1.2. Vancomycin最低抑菌濃度 4 2.1.3. 治療 5 第2-2節 Vancomycin基本性質 6 2.2.1. 臨床使用 6 2.2.2. 藥效學 6 2.2.3. 藥動學 9 2.2.4. 影響藥動學的因素 11 2.2.5. 副作用 13 2.2.6. 臨床療劑監測 15 第3章 研究目的 17 第4章 研究方法 18 第4-1節 研究設計 18 第4-2節 研究對象 18 4.2.1. 納入條件 18 4.2.2. 排除條件 18 第4-3節 研究流程 19 第4-4節 資料收集 19 4.4.1. 資料來源 19 4.4.2. 資料收集內容 19 4.4.3. 計算資料 20 4.4.4. 計算公式 20 4.4.5. 研究假設與定義 22 第4-5節 統計方法 22 第5章 研究結果 24 第5-1節 基本特性分析 24 5.1.1. 基本資料、共病症 24 5.1.2. 疾病嚴重程度 24 5.1.3. 治療分析 25 5.1.4. Ctrough 25 5.1.5. 感染分析 25 5.1.6. 菌株MIC 25 5.1.7. 群體公式計算AUC/MIC之相關資料 26 第5-2節 單變項相關性分析 27 5.2.1. 依公式計算之AUC/MIC 27 5.2.2. Ctrough 27 第5-3節 多變項相關性分析 28 5.3.1. 依公式計算之AUC/MIC 28 5.3.2. Ctrough 28 第5-4節 次族群分析 30 第5-5節 Ctrough和公式計算之AUC/MIC線性相關性 30 第6章 討論 31 第6-1節 研究族群之特性 31 第6-2節 預測30日存亡結果之PK/PD參數 32 6.2.1. 依公式計算之AUC/MIC 32 6.2.2. Ctrough 35 6.2.3. 依血中濃度計算之AUC/MIC 36 6.2.4. 副作用 37 第6-3節 研究特點與限制 38 6.3.1. 研究特點 38 6.3.2. 研究限制 38 第7章 結論 39 第8章 參考文獻 40 第9章 附錄 82 第9-1節 其他計算方式之AUC/MIC相關分析結果 82 第9-2節 MIC對30日存亡結果之影響 85 第9-3節 肥胖病人以實際體重計算相關數據之分析 85 第9-4節 依血中濃度計算之AUC/MIC 87 | |
dc.language.iso | zh-TW | |
dc.title | 預測vancomycin臨床療效之最適指標:谷藥品濃度或曲線下面積/最低抑菌濃度? | zh_TW |
dc.title | The Most Appropriate Parameter Correlates with Clinical Effectiveness of Vancomycin: Trough Drug Concentration or AUC/MIC? | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳世英(Shey-Ying Chen) | |
dc.contributor.oralexamcommittee | 林慧玲(Fe-Lin Lin Wu),薛博仁(Po-Ren Hsueh) | |
dc.subject.keyword | 萬古黴素,AUC/MIC比值,谷藥品濃度,療劑監測,藥動學,藥效學, | zh_TW |
dc.subject.keyword | Vancomycin,AUC/MIC ratio,trough concentration,therapeutic drug monitoring,pharmacokinetics,pharmacodynamics, | en |
dc.relation.page | 109 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-11 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 6.95 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。